P530 T
PRAVASTATIN THERAPY INCREASES PROCOLLAGEN I N-TERMINAL PROPEPTIDE, A MARKER OF BONE
FORMATION, IN POSTMENOPAUSAL WOMAN
C. De la Piedra*, J. M. Mostaza, M. Díaz-Curiel, R. Peña, C. Lahoz
Fundación Jiménez Díaz, Biochemistry Laboratory , Madrid, Spain.; Hospital Carlos
III, Atherosclerosis Unit, Madrid, Spain.; Fundación Jiménez Díaz, Internal Medicine,
Madrid, Spain
P533 T
EFFECTS OF LOW FREQUENCY MAGNETIC FIELDS (LFMF) ON BONE QUALITY AND BONE METABOLISM IN
OVARIECTOMIZED RATS
X. Y. Zhang*, Y. Xue
Department of Biology Engineering, Shenzhen University, Shenzhen 518060, China
P536 T
POSITIVE EFFECTS ON BMC AFTER A HIP FRACTURE. A 12 WEEK DOUBLE-BLIND STUDY WITH GROWTH
HORMONE TREATMENT
M. Hedström*, E. Brosjö, C. Hurtig, K. Sjöberg, N. Dalén
Div of Orthopedics, Karolinska Institute, Danderyd Hospital, Danderyd, Sweden; Div of
Radiology, Karolinska Institute, Danderyd Hospital, Danderyd, Sweden; Div of Geriatrics,
Karolinska Institute, Danderyd Hospital, Danderyd, Sweden
P539 T
MUSCLE/BONE BIOMECHANICAL INTERACTIONS AS AFFECTED BY GROWTH HORMONE (GH) TREATMENT IN
HYPOPHYSECTOMIZED (HX) RATS
S. Feldman*, G. R. Cointry, R. Gordon, J. L. Ferretti
Department of Immunology and Center for P-Ca Metabolism Studies, Rosario University
School of Medicine, Rosario, Argentina
P542 T
EFFECT ON BMD OF VARIOUS DOSES OF PAMIDRONATE WITH CONSTANT YEARLY DOSE: A 2 YEARS PILOT
STUDY
S. A. Fatio*, L. Sandini, O. Lamy, P. Burckhardt
Lausanne University Hospital, Switzerland
P545 T
INTRAVENOUS IBANDRONATE IN OSTEOPOROTIC MEN WITH KLINEFELTER´S SYNDROME: EFFECTS ON BONE
MINERAL DENSITY AND BIOCHEMICAL MARKERS DURING 2-YEARS TREATMENT AND AFTER WITHDRAWAL
J. J. Stepan*, P. Burckhardt, V. Hána
3rd Dept. of Internal Medicine, Charles University Faculty of Medicine, Prague, Czech
Republic; Département de médecine interne, University, Lausanne, Switzerland
P548 T
RISEDRONATE PREVENTS BONE LOSS IN MEN ON GLUCOCORTICOID THERAPY
D. J. Hosking*, D. M. Reid, J. P. Devogelaer, A. A. Chines, E. Sod
Nottingham City Hospital, Nottingham, UK; Aberdeen Royal Infirmary, Aberdeen, UK;
Louvain Catholic University, Brussells, Belgium; Procter & Gamble Pharmaceuticals,
Mason, OH, USA
P551 T
ESOPHAGEAL TRANSIT OF OVAL WAX-POLISHED ALENDRONATE TABLETS
W. M. Drake*, D. F. Worsley, B. C. Lentle, D. L. Kendler
Department of Medicine, Vancouver Hospital, BC, Canada; Department of Medical Imaging,
Vancouver Hospital, BC, Canada
P554 T
CHANGES AFTER COMPLETION OF THREE YEARS TREATMENT WITH ALENDRONATE FOR OSTEOPOROSIS
P. Kyd*, A. Fairney, E. Robinson, E. Thomas
Imperial College School of Medicine, London, UK; Department of Clinical Physics, St
Mary's NHS Trust, London, UK
P557 T
TREATMENT OF OSTEOPOROSIS IN MEN USING ALENDRONATE
E. Thomas*, A. Fairney, P. Kyd
Department of Clinical Physics, St Mary's NHS Trust, London, UK; Imperial College
School of Medicine, London, UK
P560 T
INTRAVENOUS PAMIDRONATE IN THE MANAGEMENT OF DIFFICULT OSTEOPOROSIS
P. L. Selby*, S. Vasireddy, S. Harrison, D. R. Swinson
Department of Medicine, Manchester Royal Infirmary, Manchester, UK; Wrightington
Hospital, Wigan, UK
P563 T
A RANDOMISED TRIAL OF INTRAVENOUS PAMIDRONATE AND CALCIUM & VITAMIN D IN THE TREATMENT
OF LOW BONE MINERAL DENSITY ASSOCIATED WITH CROHN'S DISEASE
S. A. Bartram*, N. P. Thompson, R. M. Francis
Musculoskeletal Unit,Freeman Hospital, Newcastle-upon-Tyne, UK; Department of
Gastroenterology, Freeman Hospital, Newcastle-upon-Tyne, UK
P566 T
EFFECT OF ALENDRONATE TREATMENT FOR THE CHINESE POSTMENOPAUSAL WOMEN WITH OSTEOPOROTIC
VERTEBRAL FRACTURES
A. P. C. Or*, W. S. Chan, E. M. C. Lau, P. C. Leung
Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Hong
Kong, PR China; Department of Community and Family Medicine, The Chinese University of
Hong Kong, Hong Kong, PR China
P569 T
RISEDRONATE IS WELL-TOLERATED IN POSTMENOPAUSAL WOMEN WHO ARE GI-INTOLERANT TO ALENDRONATE
S. Adami*, J. D. Adachi, P. D. Miller, S. Horlait
Clinicizzato di Valeggio, Valeggio, Italy; McMaster University, Hamilton, ON, Canada;
Colorado Center for Bone Research, Lakewood, CO, USA; Procter & Gamble
Pharmaceuticals, Neuilly-sur-Seine, France
P572 T
THE USE OF PAMIDRONATE TO TREAT OSTEOPOROSIS IN CHILDREN WITH SPASTIC QUADRIPLEGIC
CEREBRAL PALSY AND RECURRENT FRACTURES
S. J. Bachrach*, H. H. Kecskemethy, H. T. Harcke, F. Miller
A.I. duPont Hospital for Children, Wilmington, DE, USA; Jefferson Medical College,
Philadelphia, PA, USA
P575 T
ALENDRONATE REDUCES THE RISK OF CLINICAL VERTEBRAL FRACTURE IN OSTEOPENIC WOMEN: DATA FROM
FIT
S. A. Quandt*, D. E. Thompson, D. Schnieder, M. Nevitt, T. Musliner
Wake Forest University; Merck & Co, USA; University of California, San Francisco,
USA
P578 T
BONE MINERAL DENSITY OF ELDERLY HIP FRACTURE PATIENTS AND THE EFFECT OF CALCITONIN ON
FRACTURE FUSION
T. M. Huusko*, H. Kautiainen, R. Sulkava
Department of Public Health and General Practice, Division of Geriatrics, University of
Kuopio, Finland; Rheumatism Foundation Hospital, Heinola, Finland
P581 T
THE EFFICACY OF BIOCHEMICAL BONE MARKERS AND BONE ARCHITECTURES, STRENGTH WITH CONTINUOUS
TREATMENT OF INTRANASAL ADMINISTRATION OF SALMON CALCITONIN 200IU ON EARLY POSTMENOPAUSAL
WOMEN
I. Koulouris*, E. Kataxaki, G. Trovas, G. Skarantavos, G. Raptou, M. Katsiri, A.
Galanos, G. P. Lyritis
Laboratory for the Research of the Musculoskeletal System, University of Athens Medical
School, Athens, Greece
P582 T
THE RELATIONSHIP OF HYPOVITAMINOSIS D AND SECONDARY HYPERPARATHYROIDISM TO BONE MINERAL
DENSITY AMONGST UK RESIDENT INDO-ASIANS
E. Serhan*, M. R. Holland, B. M. Singh
Department of Rheumatology, New Cross Hospital, Wolverhampton, UK; Department of
Clinical Chemistry, New Cross Hospital, Wolverhampton, UK; Diabetes Centre, New Cross
Hospital, Wolverhampton, UK
P584 T
THE RELATIONSHIP BETWEEN VITAMIN D AND PTH: CALCIUM HOMEOSTASIS, BONE TURNOVER & BMD
IN WOMEN WITH ESTABLISHED OSTEOPOROSIS
O. Sahota*, P. San, T. Masud, D. J. Hosking
ADRU, University Hospital, Nottingham, UK; Division of Mineral Metabolism, City
Hospital, Nottingham, UK; Dept Geriatric Medicine, City Hospital, Nottingham, UK
P587 T
HIGH PROTEIN INTAKE SEEMS TO DIMINISH POSTMENOPAUSAL BONELOSS. 5 YEARS OF FOLLOW-UP ON THE
DANISH OSTEOPOROSIS PREVENTION STUDY
A. P. Hermann, L. Stilgren*, J. Thomsen, P. Vestergaard, C. Brot, N. Kolthoff, L.
Mosekilde, P. Charles
Dept of Endocrinology, Odense University Hospital, Denmark; Dept of Endocrinology,
Aarhus amtssygehus, Aarhus University Hospital, Denmark; Copenhagen Municipal Hospital,
Copenhagen, Denmark; Hillerød Hospital, Hillerød, Denmark
P590 T
RALOXIFENE EFFECTS ON BONE COULD BE ASSOCIATED WITH NITRIC OXIDE-PATHWAY
M. Lefort*, E. García-Colis, C. Méndez-Dávila, C. De la Piedra, A. Lopez-Farré, M.
Díaz-Curiel
Fundación Jiménez Díaz, Laboratorio de Bioquímica, Madrid, Spain; Fundación
Jiménez Díaz, Laboratorio de Investigación Cardiovascular e Hipertensión, Madrid,
Spain; Fundación Jiménez Díaz, Medicina Interna, Madrid, Spain
P593 T
EFFECT OF RALOXIFENE, A SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM), ON BONE RESORPTION
MARKERS AND SERUM LIPIDS IN POSTMENOPAUSAL WOMEN ON CHRONIC HEMODIALYSIS (HD)
E. Hernandez*, R. Valera, J. Teran, M. Bajares-Lilue, F. Capriles, E. Alonzo, K. de
Elquezabal, R. Carlini, E. Bellorin-Font, J. R. Weisinger
Division of Nephrology, Hospital Universitario de Caracas, Venezuela; Department of
Gynecology, Hospital Universitario de Caracas, Venezuela; Fresenius Medical Care de
Venezuela
P596 T
SKELETAL AND SOMATIC CHANGES INDUCED BY TESTOSTERONE THERAPY IN HYPOGONADAL MEN
S. V. Karlsbrum*, G. Geloso, S. Aszpis, P. Otero, L. Schurman, O. Levalle, H. Salerni
División Endocrinología, Htal Durand, Buenos Aires, Argentina; TCBA, Buenos Aires,
Argentina
P599 T
EFFECTS OF DAIDZEIN ON THE PROLIFERATION AND DIFFERENTIATION OF FEMALE PIG OSTEOBLASTS
A. De Wilde*, C. Colin, A. Pointillart, M. Lieberherr
LNSA, INRA, Jouy-en-Josas, France; CNRS UPR 1524, INRA, Jouy-en-Josas, France
P602 T
THE RELATIONSHIP OF STIFFNESS INDEX BY ULTRASOUND OF THE CALCANEUS WITH WALKING BY VITAMIN
D RECEPTOR GENOTYPE IN POSTMENOPAUSAL JAPANESE WOMEN
F. Omasu*, J. Kitagawa, Y. Nakahara
Department of Human System Science, Graduate School of Decision Science and Technology,
Tokyo Institute of Technology, Tokyo, Japan
P605 T
A TWO-YEAR PHYSICAL REHABILITATION/ EXERCISE PROGRAM DECREASES BONE LOSS AT THE HIP IN
85-YEAR OLD WOMEN
K. Kramme*, L. Puggaard, E. N. Ebbesen, B. Abrahamsen, K. Brixen
Department of Endocrinology, Odense University Hospital, Denmark; Institute of Physical
Education and Biomechanics, University of Southern Denmark; Department of Endocrinology,
Aarhus University Hospital, Denmark
P608 T
ADVANTAGES OF IMMUNOASSAYS FOR MARKERS FOR BONE RESORPTION IN PREDICTING TREATMENT
EFFICACY IN OSTEOPOROSIS ON INTERMITTENT CYCLICAL ETIDRONATE
K. Kitatani*, K. Nakatsuka, H. Naka, T. Miki, Y. Nisizawa, H. Morii
Osaka City University, Osaka, Japan; Aino Gakuin College, Ibaraki, Japan
P611 T
ACCEPTABILITY AND COMPLIANCE WITH HIP PROTECTORS BY COMMUNITY DWELLING WOMEN AT HIGH RISK
OF HIP FRACTURE
R. Wills*, L. Ogunremi, S. Patel
Osteoporosis Unit, St George's Hospital, London, UK; Dept of Rheumatology, St Helier
Hospital, Surrey, UK
P614 T
CLINICAL USEFULNESS OF BIOCHEMICAL RESORPTION MARKERS DURING ALENDRONATE TREATMENT IN
POSTMENOPAUSAL OSTEOPOROSIS
M. T. Del Campo, M. L. González Casaus, M. Bernad, M. V. Garcés, J. Fernández, M.
Pombo, M. E. Martínez*
Clinical Biochemistry Division, la Paz Hospital, Madrid, Spain; Biopathology
Department, Gómez Ulla Central Military Hospital, Madrid, Spain; Rheumatology Service, La
Paz Hospital, Madrid, Spain; Medicine and Experimental Surgery, La Paz Hospital, Madrid,
Spain
P617 T
RELATIONSHIP BETWEEN 1-YEAR CHANGE IN THE BONE TURNOVER MARKER P1NP AND 3-YEAR VERTEBRAL
FRACTURE RISK REDUCTION WITH RALOXIFENE THERAPY IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS:
RESULTS FROM THE MORE TRIAL
J. Y. Reginster*, S. Sarkar, J. Collette, B. Zegels, Y. Henrotin, O. Bruyere, M. Wong,
K. Harper, D. Agnusdei
CHU Centre-Ville, Liege, Belgium; Eli Lilly and Company, Indianapolis, USA; Eli Lilly
Italia, Florence, Italy
P620 T
CASE FINDING STRATEGIES IN OSTEOPOROSIS; PERFORMANCE OF A COMBINATION OF RISK FACTOR
ASSESSMENT AND BONE DENSITOMETRY IN THE OUT PATIENT CLINICAL DECISION-MAKING: A REPORT OF
1438 CASES
J. A. Guerrero-S*, C. Wong, J. A. Tamayo
Osteoporosis Centre, Sanatorio Español, Torreón, México; Comité Mexicano para
estudio de la Osteoporosis, México City, México
P623 T
THE COST OF OSTEOPOROSIS TREATMENT IN A DEVELOPING COUNTRY: THE ECUADORIAN MODEL
V. M. Pacheco*, M. Miranda
Universidad Central del Ecuador - Pontificia Universidad Catolica del Ecuador -
Superintendencia de Bancos, PO Box 17-03-775, Quito, Ecuador
P626 T
EVALUATION OF THE DIFFERENTIAL SKELETAL EFFECTS OF RHPTH IN THE OVARIECTOMIZED RHESUS
MONKEY BY BONE DENSITOMETRY
S. Y. Smith*, C. Chevrier, A. J. Metcalfe, J. Fox, M. A. Miller, M. K. Newman
CTBR, Senneville, QC, Canada; NPS Pharmaceuticals, UT, USA
P629 T
ECONOMIC COMPARISON OF DIAGNOSTIC APPROACHES FOR EVALUATING OSTEOPOROSIS IN OLDER WOMEN
D. F. Kraemer*, H. D. Nelson, D. C. Bauer, M. Helfand
Oregon Health Sciences University, Portland, Oregon, USA; Portland Veterans Affairs
Medical Center; University of California San Francisco, San Francisco, California, USA
P632 T
FREQUENCY OF HYPERCALCEMIA IN PATIENTS TREATED WITH ALFACALCIDOL
W. F. Lems*, F. van Berkum
Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands; Ziekenhuis Twente,
Twente, The Netherlands
P635 T
THE REDUCED BONE FORMATION AND STRENGTH IN CARBON TETRACHLORIDE INDUCED HEPATIC
OSTEODYSTROPHY ARE PARTIALLY PRVENTED BY ADMINISTRATION OF 1.25(OH)2D
S. Tanaka*, A. Sakai, H. Tsurukami, N. Okimoto, H. Otomo, T. Nakamura
Department of Orthopaedic Surgery, University of Occupational and Environmental Health,
Japan
P638 T
EFFECT OF CALCITRIOL ON BONE METABOLISM IN INSTITUTIONALIZED EPILEPTIC PATIENTS
M. A. Krieg*, J. Fritschi, F. Baronti, P. Burckhardt
University Hospital, Lausanne; Bethesda Klinik, Tschugg, Switzerland
P641 T
THE INFLUENCE OF VITAMIN D3 AND CALCIUM ON OSTEOPOROTIC FRACTURE HEALING
A. M. Doetsch*, N. Lynnerup, J. Faber, H. Bliddal, P. Beck, B. Danneskiold-Samsoe
Parker Institute, Frederiksberg Hospital, Denmark; Panum Institute, University of
Copenhagen, Denmark
